Emelia Ansu-Gyeabourh Email & Phone Number

United States

Cambridge, Massachusetts, United States

• Sana Biotechnology company, established in 2018, is creating and delivering in-vivo and ex-vivo cell and gene therapies
• Successfully developed complex cell-based potency assays (Luciferase reporter assay for cytotoxicity and MSD for TNFα, IFNγ and Gzm cytokine secretion assays) under tight deadlines. Methods aided to monitor the potency.
• Served as SME in LVV potency assay development, collaborated in training the team and led potency meeting series between ex-vivo (SG291 currently in clinical stage) and in-vivo (SG299) CAR T programs.
• Developed residual endonuclease methods to monitor process impurities. Authored and transferred technology reports to CDMO, followed through as SME to the successful execution of transferred methods.
• Collaborated with protein engineering team and discovered factors affecting transduction in a choice of engineered cell line, which guided strategy for potency method development
• Presented analytical updates at CMC meetings.

Cambridge, Massachusetts, United States

• Set a rigorous and gold standard in analytical method development and implemented control strategy that validated data reported from various assays.
• Collaborated with protein engineering team to identify critical reagents needed for MSD immunoassay methods development. Led collaborations with external vendors to manufacture these reagents.
• Developed three MSD methods to characterize viral envelope proteins. Transferred methods to analytical testing and protein engineering teams. The methods guided process improvement to the manufacturability of a highly.
• Received “On the Spot Bonus” award for generating key decision-making data under tight timelines.
• Authored SOPs and technical reports for IND.
• Trained and mentored junior scientists including direct report, on method development and presentation skills.

Boston, Massachusetts, United States

• MassBiologics, a biotechnology company established in 1896 manufactures vaccines, research and develops other biologics, mostly mAbs. Massbiologics additionally conducts CMO services including gene therapy products and.
• Principal Lead for Lyme project. Conducted formulation development and stability studies, presented analytical updates at CMC meetings, effectively transferred all assays to QC, authored comprehensive technology.
• Managed an HIV project by assigning tasks to analysts and ensured efficient execution.
• Developed HPLC methods for co-formulated mAbs that guided product purity.
• Established a robust method for cIEF on Agilent instrument CE 7100 (transferred to QC)
• Utilized mass spectrometry (paper spray, ESI) for compound identification and reaction studies, resulting in two publications.

• Created and led research associates’ data presentation meeting series, that enhanced visibility and team engagement across upstream, downstream, and analytical teams.
• Developed a robust relative potency ELISA assay for a complex co-formulated broadly neutralizing antibodies at tight deadline and transferred to QC.
• Developed and transferred cell-based potency assay for aromatic l-amino acid decarboxylase expression assay for AAV gene therapy product.
• Created an affinity HPLC method, and optimized qPCR assay for AAV viral vector characterization
• Streamlined amino acid analysis method on waters UPLC, that ensured quick turnaround data to support spent media analysis.
• Authored various SOPs, IP forms, technical and technology reports for various developed methods.

Boston, Massachusetts, United States

• Successfully completed formulation development screening with varied ionic strength, pH, and excipients, and selected the best formulation for DS and DP for diphtheria mAb using stability indicating assays.
• Developed SEC-HPLC method that completely resolved tailing effect and ensured accurate quantitation of diphtheria mAb product.
• Developed hemagglutination assay to release cell bank for clinical studies. For detection of the presence of CFA/1 on the surface of enterotoxigenic E. coli (ETEC) and transferred method to discovery team.
• Completed SOPs, IP forms, technical and technology reports.

Boston, Massachusettes

• Run testing on samples and reported results promptly to Upstream and Downstream teams that enhanced productivity for manufactured and purified mAb samples using spectrophotometer (A280nm), HPLC, CE for SDS, cIEF and.
• Analyzed spent media samples for levels of phosphate, pyruvate, choline, and amino acids to support cell culture media development for CHO cell line for mAb production.
• Investigated and presented data on the discovery of the root cause of dark coloration issue in cell culture feed media. Findings led to complete elimination of issue in upstream composed media for mAb production.
• Optimized HPLC method for Rabies quantification and contributed to SOPs and technical reports.

Boston, Massachusetts, United States

• Conducted filling of licensed Tetanus and Diphtheria Toxoids Adsorbed (Td) vaccines in compliance with current Good Manufacturing Practices (cGMP)

Greater Boston

• Performed visual inspections of licensed Tetanus and Diphtheria Toxoids Adsorbed (Td) vaccines in accordance with current Good Manufacturing Practices (cGMP).

Boston, Massachusetts, United States

Port Sunlight, England, United Kingdom

• Worked in a cGMP-regulated facility as part of a team in the analysis of fabric washing liquids. Efficiently measured and promptly reported results for pH, viscosity, and water content (KF) in intermediate and final.

Loughborough, England, United Kingdom

• Investigated the selectivity of Iridium, Palladium and Platinum heterogeneous catalysts in hydrogenation reactions and used HPLC, LCMS, GCMS, IR and proton NMR for analysis.